+Follow
Hlaing
No personal profile
37
Follow
1
Followers
0
Topic
0
Badge
Posts
Hot
Hlaing
2022-02-03
Great ariticle, would you like to share it?
Merck Clocked $950M Sales In Q4 From COVID-19 Treatment, Issues FY22 Sales
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4089941566747690","uuid":"4089941566747690","gmtCreate":1626838608286,"gmtModify":1655127023429,"name":"Hlaing","pinyin":"hlaing","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/296d8d5b8ae59869cfb743c360f9cd51","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":37,"tweetSize":1,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.04.17","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.30","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"60.22%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":32,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9091531537,"gmtCreate":1643896758116,"gmtModify":1676533868765,"author":{"id":"4089941566747690","authorId":"4089941566747690","name":"Hlaing","avatar":"https://community-static.tradeup.com/news/296d8d5b8ae59869cfb743c360f9cd51","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089941566747690","authorIdStr":"4089941566747690"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091531537","repostId":"2208239641","repostType":2,"repost":{"id":"2208239641","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1643895235,"share":"https://ttm.financial/m/news/2208239641?lang=&edition=fundamental","pubTime":"2022-02-03 21:33","market":"us","language":"en","title":"Merck Clocked $950M Sales In Q4 From COVID-19 Treatment, Issues FY22 Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2208239641","media":"Benzinga","summary":"Merck & Co Inc's (NYSE: MRK) Q4 sales re","content":"<html><body><p><strong>Merck & Co Inc's</strong> (NYSE:MRK) Q4 sales reached $13.52 billion, +24% Y/Y, beating the consensus of $13.16 billion. </p>\n<ul>\n<li>Excluding the foreign exchange impact, revenues were up 23%.</li>\n<li>Pharmaceutical sales increased 23% to $12 billion, reflecting sales of molnupiravir and growth in oncology, vaccines, and hospital acute care products. </li>\n<li>COVID-19 treatment drug Molnupiravir sales were $952 million, primarily consisting of sales in the U.S., the U.K., and Japan.</li>\n<li><strong><em>Related:</em></strong><em> </em><em>Merck's COVID-19 Pill works Against Omicron, Lab Studies Show</em>.</li>\n<li>Keytruda sales grew 15% to $4.6 billion. Vaccine sales rebounded, and Gardasil/ Gardasil 9 sales were up 53% to $1.5 billion, primarily driven by strong global demand, particularly in China.</li>\n<li>Vaccine performance was negatively affected by lower sales of PNEUMOVAX 23 pneumococcal vaccine, which declined 14% to $292 million on lower demand in the U.S., reflecting prioritization of COVID-19 vaccines.</li>\n<li>Adjusted EPS of $1.80 also surpassed the analysts' estimate of $1.53 and up from $0.98 posted a year ago.</li>\n<li><strong>2022 Guidance:</strong> Merck expects FY22 sales of $56.1 billion - $57.6 billion, compared to the consensus of $56.64 billion.</li>\n<li>It expects an adjusted EPS of $7.12 and $7.27 (consensus $7.29).</li>\n<li><strong>Price Action:</strong> MRK shares are down 0.33% at $81.74 during the premarket session on the last check Thursday.</li>\n</ul>\n</body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck Clocked $950M Sales In Q4 From COVID-19 Treatment, Issues FY22 Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck Clocked $950M Sales In Q4 From COVID-19 Treatment, Issues FY22 Sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2022-02-03 21:33</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong>Merck & Co Inc's</strong> (NYSE:MRK) Q4 sales reached $13.52 billion, +24% Y/Y, beating the consensus of $13.16 billion. </p>\n<ul>\n<li>Excluding the foreign exchange impact, revenues were up 23%.</li>\n<li>Pharmaceutical sales increased 23% to $12 billion, reflecting sales of molnupiravir and growth in oncology, vaccines, and hospital acute care products. </li>\n<li>COVID-19 treatment drug Molnupiravir sales were $952 million, primarily consisting of sales in the U.S., the U.K., and Japan.</li>\n<li><strong><em>Related:</em></strong><em> </em><em>Merck's COVID-19 Pill works Against Omicron, Lab Studies Show</em>.</li>\n<li>Keytruda sales grew 15% to $4.6 billion. Vaccine sales rebounded, and Gardasil/ Gardasil 9 sales were up 53% to $1.5 billion, primarily driven by strong global demand, particularly in China.</li>\n<li>Vaccine performance was negatively affected by lower sales of PNEUMOVAX 23 pneumococcal vaccine, which declined 14% to $292 million on lower demand in the U.S., reflecting prioritization of COVID-19 vaccines.</li>\n<li>Adjusted EPS of $1.80 also surpassed the analysts' estimate of $1.53 and up from $0.98 posted a year ago.</li>\n<li><strong>2022 Guidance:</strong> Merck expects FY22 sales of $56.1 billion - $57.6 billion, compared to the consensus of $56.64 billion.</li>\n<li>It expects an adjusted EPS of $7.12 and $7.27 (consensus $7.29).</li>\n<li><strong>Price Action:</strong> MRK shares are down 0.33% at $81.74 during the premarket session on the last check Thursday.</li>\n</ul>\n</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","BNTX":"BioNTech SE"},"source_url":"https://www.benzinga.com/general/biotech/22/02/25389519/merck-clocked-950m-sales-in-q4-from-covid-19-treatment-issues-fy22-sales","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208239641","content_text":"Merck & Co Inc's (NYSE:MRK) Q4 sales reached $13.52 billion, +24% Y/Y, beating the consensus of $13.16 billion. \n\nExcluding the foreign exchange impact, revenues were up 23%.\nPharmaceutical sales increased 23% to $12 billion, reflecting sales of molnupiravir and growth in oncology, vaccines, and hospital acute care products. \nCOVID-19 treatment drug Molnupiravir sales were $952 million, primarily consisting of sales in the U.S., the U.K., and Japan.\nRelated: Merck's COVID-19 Pill works Against Omicron, Lab Studies Show.\nKeytruda sales grew 15% to $4.6 billion. Vaccine sales rebounded, and Gardasil/ Gardasil 9 sales were up 53% to $1.5 billion, primarily driven by strong global demand, particularly in China.\nVaccine performance was negatively affected by lower sales of PNEUMOVAX 23 pneumococcal vaccine, which declined 14% to $292 million on lower demand in the U.S., reflecting prioritization of COVID-19 vaccines.\nAdjusted EPS of $1.80 also surpassed the analysts' estimate of $1.53 and up from $0.98 posted a year ago.\n2022 Guidance: Merck expects FY22 sales of $56.1 billion - $57.6 billion, compared to the consensus of $56.64 billion.\nIt expects an adjusted EPS of $7.12 and $7.27 (consensus $7.29).\nPrice Action: MRK shares are down 0.33% at $81.74 during the premarket session on the last check Thursday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":210,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9091531537,"gmtCreate":1643896758116,"gmtModify":1676533868765,"author":{"id":"4089941566747690","authorId":"4089941566747690","name":"Hlaing","avatar":"https://community-static.tradeup.com/news/296d8d5b8ae59869cfb743c360f9cd51","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089941566747690","authorIdStr":"4089941566747690"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091531537","repostId":"2208239641","repostType":2,"isVote":1,"tweetType":1,"viewCount":210,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}